{"id":506,"date":"2013-05-23T15:01:06","date_gmt":"2013-05-23T15:01:06","guid":{"rendered":"http:\/\/iatdmct.com\/?page_id=506"},"modified":"2013-09-21T04:15:06","modified_gmt":"2013-09-21T04:15:06","slug":"poster-presentations","status":"publish","type":"page","link":"http:\/\/iatdmct.com\/?page_id=506","title":{"rendered":"Poster Presentations"},"content":{"rendered":"

1500-1600 MONDAY AFTERNOON<\/span><\/p>\n

AN INTERNATIONAL INTERLABORATORY QUALITY CONTROL (QC) PROGRAM FOR BIO-ANALYSIS OF TUBERCULOSIS DRUGS.<\/span>
\nAarnoutse R<\/span>1,2<\/sup>, Robijns K2<\/sup>, Harteveld A2<\/sup>, Greijdanus B3<\/sup>, Uges D2,3<\/sup>, Touw D2<\/sup>, Alffenaar J.W.3<\/sup> 1<\/sup> Dept. of Pharmacy, Radboud University Medical Centre, Nijmegen, The Netherlands, 2<\/sup>. KKGT: Association for Quality Assessment in TDM and Clinical Toxicology, The Hague, The Netherlands (www.KKGT.nl), 3<\/sup>. Dept. of Hospital and Clinical Pharmacy, University Medical Centre Groningen, Groningen, The Netherlands<\/span><\/p>\n

WEIGHT STATUS AND THE EFFECT ON DOSING VANCOMYCIN IN PEDIATRIC PATIENTS.<\/span>
\nWeston, A.S.<\/span>1<\/sup>, Constance, J.E.1<\/sup>, Sherwin, C.M.T1<\/sup>, Campbell, S.C1<\/sup>, Stockmann, C.1<\/sup>, Mihalopoulos, N.L.2<\/sup>, Korgenski, E.K.3<\/sup>, Spigarelli, M.G.1,2<\/sup> 1<\/sup>Dept. of Pediatrics, Div. of Clinical Pharmacology, University of Utah. 2<\/sup>Dept. of Pediatrics, Div. of Adolescent Medicine, University of Utah. 3<\/sup>Intermountain Healthcare, Pediatric Clinical Program, University of Utah<\/span><\/p>\n

DETERMINATION OF AMIKACIN PHARMACOKINETIC PARAMETERS IN KUWAITI HOSPITALIZED PATIENTS.<\/span>
\nAl-lanqawi Y1<\/sup>, Matar K2<\/sup>, Abudlmalek K3<\/sup>, Thusu A4<\/sup>, Jelliffe R5<\/sup>. 1<\/sup>Departments of Pharmacy – Drug and poison information & Research Unit, 3<\/sup>Intensive Care and 4<\/sup>Medicine, Al-Amiri Hospital, Ministry of Health, Kuwait; Department of 2<\/sup>Applied Therapeutics, Faculty of pharmacy -Kuwait University;5<\/sup>Laboratory of Applied Pharmacokinetics, School of Medicine, University of Southern California, LA, USA.<\/span><\/p>\n

RATES OF OXYCODONE IN HAIR AND MECONIUM BEFORE AND AFTER THE RELEASE OF OXYNEO IN CANADA.<\/span>
\nCarnevale, A<\/span>1,2<\/sup>, Gareri, J1<\/sup>, Walasek, P1<\/sup>, Karaskov, T1<\/sup>, Koren, G1,2,3<\/sup> 1<\/sup>Motherisk Laboratory, The Hospital for Sick Children, Toronto, Canada; 2<\/sup>Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada; 3<\/sup>Ivey Chair in Molecular Toxicology, University of Western Ontario, London, Canada.<\/span><\/p>\n

PROLONGED ELIMINATION TIME OF PALIPERIDONE AFTER ADMINISTRATION OF PALIPERIDONE PALMITATE DEPOT INJECTIONS.<\/span>
\nHelland A<\/span>1<\/sup>, Syrstad VEG2<\/sup>, Spigset O1,3<\/sup>. 1<\/sup> Dept. of Clinical Pharmacology, St. Olav University Hospital, Trondheim, Norway. 2<\/sup>Division of Mental Health Care, St. Olav University Hospital, Trondheim, Norway. 3<\/sup>Dept. of Laboratory Medicine, Children\u2019s and Women\u2019s Health, Norwegian University of Science and Technology, Trondheim, Norway.<\/span><\/p>\n

IMPORTANCE OF THERAPEUTIC DRUG MONITORING (TDM) OF FLECAINIDE FOR PAROXYMAL SUPRAVENTRICULAR TACHYCARDIA IN CHILDREN IN THE FIRST YEAR OF LIFE.<\/span>
\nBartoli A.N.<\/span>1<\/sup>, Mannarino, S2<\/sup>, Broglia M1<\/sup> Codazzi A2<\/sup>, Magrassi S4<\/sup>, Stronati M3<\/sup>, Regazzi M1<\/sup>. 1<\/sup>Unit of Clinical and Experimental Pharmacokinetics, 2<\/sup>Pediatric Cardiology, Pediatric Department, 3<\/sup>Neonatal Intensive Care Unit Foundation IRCCS Policlinico San Matteo, Pavia, Italy. 4<\/sup>Pediatric Medical School University of Pavia, Italy.<\/span><\/p>\n

INSUFFICIENT SERUM CASPOFUNGIN LEVELS IN A PAEDIATRIC PATIENT ON ECMO.<\/span>
\nKoch BCP<\/span>1<\/sup>, Wildschut ED2<\/sup>, Goede de AL1<\/sup>, Hoog de M2<\/sup>, Br\u00fcggemann RJM3<\/sup>
\n1<\/sup>Dept. Hospital Pharmacy, Erasmus MC, Rotterdam, the Netherlands, 2<\/sup>Dept. Intensive Care Sophia\u2019s Children\u2019s Hospital, Erasmus MC, Rotterdam, the Netherlands, 3<\/sup>Clinical Pharmacy and Nijmegen Institute for Infection, Inflammation and Immunity, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.<\/span><\/p>\n

PHARMACOKINETICS OF VEMURAFENIB IN A PATIENT WITH METASTATIC MELANOMA AND RENAL FAILURE ON HEMODIALYSIS. A CASE REPORT<\/span>
\nBroglia M<\/span>1<\/sup>, Bartoli A.N.1<\/sup>, Valentino F2<\/sup>, Esposito P3<\/sup>, Montagna M1<\/sup>, Pedrazzoli P2<\/sup>. 1<\/sup>Unit of Clinical and Experimental Pharmacokinetics, 2<\/sup>Section of Oncology and 3<\/sup>Unit of Nephrology, Dialysis and Transplantation Foundation IRCCS Policlinico San Matteo, Pavia, Italy.<\/span><\/p>\n

ANALYTICAL CHALLENGES IN DRIED BLOOD SPOT AND PLASMA SAMPLING FOR THERAPEUTIC DRUG MONITORING OF ANTIEPILEPTIC DRUGS.<\/span>
\nLinder C<\/span>, Andersson M, Mahindi M, Olof Beck, Pohanka A. Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska University hospital and Karolinska Institute, Stockholm, Sweden.<\/span><\/p>\n

PROOF OF CONCEPT: A PROTOTYPE ASSAY FOR HIGH SPEED IMATINIB QUANTITATION BY IMMUNOASSAY.<\/span>
\nBaldasano CN, Jarrah J, Glass E, Courtney J, Cline DJ<\/span>, Baburina I, Salamone SJ. Saladax Biomedical, Inc., Bethlehem, PA, USA.<\/span><\/p>\n

LC-MS\/MS OF ATYPICAL ANTIPSYCHOTICS IN DRIED BLOOD SPOTS.<\/span>
\nFisher DS<\/span>, Partridge SJ, Flanagan RJ. Toxicology Unit, King\u2019s College Hospital, London, UK.<\/span><\/p>\n

POOR PERFORMANCE OF LABORATORIES ASSAYING NEWLY DEVELOPED ANTIRETROVIRAL AGENTS: RESULTS FOR DARUNAVIR, ETRAVIRINE AND RALTEGRAVIR FROM THE INTERNATIONAL QUALITY CONTROL PROGRAM FOR MEASUREMENT OF ANTIRETROVIRAL DRUGS IN PLASMA.<\/span>
\nBurger D<\/span>1<\/sup>, Krens S1<\/sup>, Robijns K2<\/sup>, Aarnoutse R1<\/sup>, Br\u00fcggemann R1<\/sup>, Touw D2<\/sup>. 1<\/sup>Department of Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. 2<\/sup>KKGT: Dutch Association for Quality Assessment in Therapeutic Drug Monitoring & Clinical Toxicology, The Hague, The Netherlands(www.kkgt.nl<\/a>).<\/span><\/p>\n

SPOTLIGHT ON THE PATTERN OF DRUG ABUSE AND THE MOST CONSUMED DRUGS FOR EGYPTIANS IN THE PERIOD 2007-2012.<\/span>
\nEL Desoky ES<\/span>, Hamdi MM, Farghaly HS, Abdelzaher LA, Hareedy MS, Taha AF, and Molla MS. Pharmacology Department, and drug monitoring and abuse lab, Assiut Faculty of Medicine and University Hospital, Assiut, Egypt.<\/span><\/p>\n

THE EFFECT OF GESTATIONAL AGE ON THE INSULIN TO C-PEPTIDE RATIO IN NEONATES.<\/span>
\nSalis E.R<\/span>1<\/sup>, Reith D.M2<\/sup>, Broadbent R.S2<\/sup>, Wheeler B.J2<\/sup>, Medlicott N.J1<\/sup>. 1<\/sup>New Zealand\u2019s National School of Pharmacy, University of Otago, Dunedin.2<\/sup>Dunedin School of Medicine, University of Otago, Dunedin.<\/span><\/p>\n

INAPPROPRIATE RESPOND TO TREATMENT DUE TO DRUG INTERACTION BETWEEN VALPROIC ACID AND CARBAPENEMS.<\/span>
\nHalacova M<\/span>1<\/sup>, Ticha J.2<\/sup>, Hyanek T.3<\/sup>, Cerny, D.1<\/sup>, Gallusova, J.1<\/sup>. 1<\/sup>Department of Clinical Pharmacy, Hospital Homolka, Prague. 2<\/sup>Department of Clinical Biochemie, Hematology and Imunology, Hospital Homolka, Prague.3<\/sup> Department of Anaesthesia and Intensive care, Hospital Homolka, Prague.<\/span><\/p>\n

BREAST-FED INFANTS WHOSE, MOTHERS WERE ON PLATINUM BASED CHEMOTHERAPY: CASES WITH PROMISING OUTCOMES.<\/span>
\nTesfaye H<\/span>1<\/sup>, Halaska M.J.2<\/sup>, Branova P1<\/sup>, Prusa R1<\/sup>, Rob L2<\/sup>, Skultety J2<\/sup>, Robova H2<\/sup>. 1<\/sup>Department of Medical Chemistry and Clinical Biochemistry, Division of Clinical Pharmacology. 2<\/sup>Department of Obstetrics and Gynecology, Faculty Hospital in Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.<\/span><\/p>\n

IMPACT OF P-GLYCOPROTEIN AND BREAST CANCER RESISTANCE PROTEIN ON THE BRAIN DISTRIBUTION OF ANTIEPILEPTIC DRUGS.<\/span>
\nYano I<\/span>1<\/sup>, Nakanishi H1<\/sup>, Yonezawa A2<\/sup>, Matsubara K2<\/sup>. 1<\/sup>Department of Clinical Pharmacy and Education, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan. 2<\/sup>Department of Pharmacy, Kyoto University Hospital, Kyoto, Japan.<\/span><\/p>\n

VANCOMYCIN REMOVAL DURING LOW-FLUX AND HIGH-FLUX EXTENDED DAILY HEMODIALYSIS IN CRITICALLY ILL SEPTIC PATIENTS.<\/span>
\nKacirova I<\/span>1,2<\/sup>, Petejova N4<\/sup>, Duricova J1,2<\/sup>, Urbanek K3<\/sup>, Grundmann M2<\/sup>, Martinek A4<\/sup>, Brozmanova H1,2<\/sup>, Zahalkova J5,6<\/sup>. 1<\/sup> Department of Clinical Pharmacology University Hospital Ostrava. 2<\/sup>Department of Clinical Pharmacology Faculty of Medicine University of Ostrava. 3<\/sup>Department of Pharmacology Faculty of Medicine Palacky University Olomouc and University Hospital Olomouc. 4<\/sup>Department of Internal Medicine Faculty of Medicine University of Ostrava and University Hospital Ostrava. 5<\/sup>Department of Internal Medicine University Hospital Olomouc and Faculty of Medicine Palacky University Olomouc. 6<\/sup>Stredomoravska nemocnicni Hospital Sternberk.<\/span><\/p>\n

TDM OF AMINOGLYCOSIDE ANTIBIOTICS AND VANCOMYCIN AS AN INDICATOR OF THE QUALITY OF MEDICAL CARE IN UNIVERSITY HOSPITAL OSTRAVA -RESULTS OF THE 3-YEARS MONITORING.<\/span>
\nKacirova I<\/span>1,2<\/sup>, Grundmann M2<\/sup>, Sistik P1<\/sup>. 1<\/sup>Department of Clinical Pharmacology University Hospital Ostrava and 2<\/sup>Department of Clinical Pharmacology Faculty of Medicine University of Ostrava.<\/span><\/p>\n

THERAPEUTIC DRUG MONITORING OF ANTIEPILEPTIC DRUGS DURING PREGNANCY.<\/span>
\nRitchie JC<\/span>1<\/sup>, Scott-Harrell P1<\/sup>, Ramsey C.H.1<\/sup> and Lukacin R2<\/sup>. 1<\/sup>Emory University School of Medicine, Atlanta, Georgia, USA. 2<\/sup> Chromsystems Instrument & Chemicals GmbH, Am Haag 12, 82166 Gr\u00e4felfing\/Munich, Germany.<\/span><\/p>\n

LMP1-CD40 MOUSE MODEL OF LYMPHOMA: A NEW MODEL TO EVALUATE THE LYMPHOMAGENESIS POTENTIAL OF IMMUNOSUPPRESSANTS.<\/span>
\nStojanova, J1,2<\/sup>, David A2,3<\/sup>, Feuillard J2,3,4<\/sup>, Zimber-Strobl U5<\/sup>, Marquet P1,2,4<\/sup>, Faumont N2,3<\/sup>. 1<\/sup>Inserm, UMR S-850, Limoges, France; 2<\/sup>Universit\u00e9 de Limoges, France; 3<\/sup>CNRS UMR 7276, Limoges, France ; 4<\/sup>CHU de Limoges, France; 5<\/sup>Klinische Molekularbiologie und Tumorgenetik, Helmholtz Center, Munich, Germany.<\/span><\/p>\n

DETERMINATION OF AN INITIAL DOSE OF GENTAMICIN: EVALUATION OF 5 NOMOGRAMS IN A KOREAN POPULATION.<\/span>
\nJieon Lee, Seonghae Yoon, MD, Donghoon Shin, MD, Kyoung Soo Lim, MD, PhD, In-Jin Jang, MD, PhD, Howard Lee, MD, PhD, Sang-Goo Shin, MD, PhD, Kyung-Sang Yu, MD, PhD. Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.<\/span><\/p>\n

METHADONE PHARMACOKINETICS IN AN OBESE PATIENT.<\/span>
\nKapur, B. M.<\/span> Department of Clinical Pathology, Sunnybrook Health Sciences Centre, Division of Clinical Pharmacology and Toxicology, Hospital for Sick Children and Department of Laboratory Medicine and Pathobiology, University of Toronto, and Canadian Medical laboratories, Mississauga, ON.<\/span><\/p>\n

ASSOCIATION OF SERUM CYTOKINE PROFILES WITH TACROLIMUS-INDUCED CHRONIC NEPHROTOXICITY IN CHINESE LIVER TRANSPLANT RECIPIENTS.<\/span>
\nJiangtao Tang1<\/sup>, Yunying Shi2<\/sup>, Junlong Zhang1<\/sup>, Yi Li1<\/sup>, Yunfei An1<\/sup>, Lanlan Wang1*<\/sup>. 1<\/sup>Department of Laboratory Medicine, West China Hospital of Sichuan University, No. 37 Guoxue Road, Chengdu 610041, P. R. China. 2<\/sup>Department of Nephrology, West China Hospital of Sichuan University, No. 37 Guoxue Road, Chengdu 610041, P. R. China. *<\/sup>Corresponding author. Tel.: +86 28 85422751 Fax: +86 28 85422751, E-mail address: wanglanlan999@163.com<\/a><\/span><\/p>\n

INFLUENCE OF CYP3A5, CYP2C8 AND ABCB1 POLYMORPHISMS ON TACROLIMUS-INDUCED NEPHROTOXICITY IN LIVER TRANSPLANT RECIPIENTS.<\/span>
\nYunying Shi2<\/sup>, Jiangtao Tang1<\/sup>, Junlong Zhang1<\/sup>, Yunfei An1<\/sup>, Yun Liao1<\/sup> ,Yi Li1<\/sup>, Lanlan Wang1*<\/sup>. 1<\/sup>Department of Laboratory Medicine, West China Hospital of Sichuan University. Chengdu, Sichuan ,China. 2<\/sup>Department of nephrology, West China hospital of Sichuan University, Chengdu, Sichuan,China.
\n*<\/sup>Correspondence: Lanlan Wang, MD, PhD, Department of Laboratory Medicine,West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, P. R.China.Tel.:+86 028 85422751 Fax: +86 028 85422751 Email:wanglanlan999@163.com<\/a><\/span><\/p>\n

DEVELOPMENT AND ASSESSMENT OF NEW HYDROGELS FOR NON-INVASIVE IONTOPHORETIC SKIN SAMPLING.<\/span>
\nNogueiras-Nieto L, Blyth A, Butcher E, Carter L, Harrison R and Delgado-Charro MB<\/span>. Department of Pharmacy and Pharmacology, University of Bath, UK.<\/span><\/p>\n

TDM IN CLINICAL LABORATORY – DRUG INTERACTIONS INVOLVING MOST OFTEN INDICATED FIRST- AND SECOND-GENERATION ANTICONVULSANTS. INCIDENCE OF ALCOHOL ABUSE IN THE GROUP OF PATIENTS TREATED FOR EPILEPSY.<\/span>
\nPolok Rajska M<\/span>1<\/sup>, Loucka P1<\/sup>, Minar J1<\/sup>, Horna A2<\/sup>. 1<\/sup>SPADIA LAB a.s., Ostrava (Czech Republic), 2<\/sup>RADANAL s.r.o., Pardubice (Czech Republic).<\/span><\/p>\n

A COMPARISON OF TWO REGIMENS (EXTENDED VERSUS SHORT INFUSION) OF MEROPENEM IN AN INTENSIVE CARE UNIT.<\/span>
\nMathew SK<\/span>1<\/sup>, Mathew BS1<\/sup>, Naik GS1<\/sup>, Gupta RP1<\/sup>, Subramani K.2<\/sup>, Jacob GG2<\/sup>, Fleming D.H1<\/sup>. 1<\/sup>Department of Pharmacology and Clinical Pharmacology, 2<\/sup> Surgical Intensive Care Unit, division of Critical Care, Christian Medical College, Vellore 632 004, Tamil Nadu, India.<\/span><\/p>\n

FREQUENCY OF VANCOMYCIN TARGET TROUGH ATTAINMENT FOR CUTANEOUS AND INVASIVE STAPHYLOCOCCAL INFECTIONS.<\/span>
\nLinakis, M.W.<\/span>, Constance, J.E., Stockmann, C., Campbell, S.C., Sherwin, C.M.T., Spigarelli, M.G. Dept. of Pediatrics, Div. of Clinical Pharmacology, University of Utah.<\/span><\/p>\n

EFFECT OF CYCLOSPORINE A AND ITS METABOLITES ON DIURNAL BLOOD PRESSURE VARIABILITY.<\/span>
\nGrundmann M<\/span>1<\/sup>, Kacirova I1, 2<\/sup>, Halvova P2<\/sup>, Brozmanova H1,2<\/sup>. 1<\/sup>Department of Clinical Pharmacology Faculty of Medicine University of Ostrava and 2<\/sup>Department of Clinical Pharmacology University Hospital Ostrava.<\/span><\/p>\n

ULTRAFAST QUANTITATIVE ANALYSIS OF SMALL MOLECULES IN SERUM AND URINE USING AN ONLINE SPE\/MS\/MS SYSTEM.<\/span>
\nYoussef. M., Miller.V.<\/span>, LaMarr. W. Agilent Technologies, Wakefield, MA.<\/span><\/p>\n

RELATIONSHIP BETWEEN BLOOD GLUCOSE LEVELS AND SERUM HEAVY AND TRACE METALS CONCENTRATIONS OF TYPE 2 DIABETICS AT THE OBAFEMI AWOLOWO UNIVERSITY TEACHING HOSPITAL COMPLEX, Ile-Ife.<\/span>
\nAfolabi O. T M.B.Ch.B, M.P.H; Olawande O B.Sc. Biochemistry, M.P.H<\/span>. Department of Community Health, College of Health Sciences, Obafemi Awolowo University, Ife, Nigeria.<\/span><\/p>\n

APPLICATION OF DRUG TESTING USING EXHALED BREATH IN A CRIMINAL JUSTICE SETTING<\/span>
\nBeck O<\/span>, Stephanson N, Shafaati M, Sandqvist S. Department of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden.<\/span><\/p>\n

SEVERE DECREASE OF CYCLOSPORINE LEVELS IN A HEART TRANSPLANT RECIPIENT RECEIVING THE DIRECT THROMBIN INHIBITOR ARGATROBAN.<\/span>
\nSanchez R1<\/sup>, Picard N2<\/sup>, Mouly-Bandini A3<\/sup>, Collart F3<\/sup>, Lacarelle B1<\/sup>, Sampol-Manos E1<\/sup>.
\n1<\/sup>Phamacokinetic and toxicology department CHU timone Marseille France; 2<\/sup>Inserm, UMR-S850, Limoges, France; 3<\/sup>Cardiac surgery department CHU Timone, Marseille, France.<\/span><\/p>\n

EVALUATION OF ASSAY TECHNIQUES FOR THE MEASUREMENTS OF AMIKACIN, GENTAMICIN AND VANCOMYCIN IN SERUM: RESULTS FROM THE BELGIAN EXTERNAL QUALITY ASSESSMENT SCHEME.<\/span>
\nDelattre IK1<\/sup>, Soumali R1<\/sup>, Van de Walle P1<\/sup>, Wallemacq P<\/span>2<\/sup>. 1<\/sup>Quality of Medical Laboratories, Scientific Institute of Public Health, Belgium. 2<\/sup>Laboratory of Toxicology and Therapeutic Drug Monitoring, Universit\u00e9 catholique de Louvain, Saint-Luc Hospital, Belgium.<\/span><\/p>\n

HOW APPROPRIATE IS THERAPEUTIC DRUG MONITORING FOR LITHIUM? DATA FROM THE BELGIAN EXTERNAL QUALITY ASSESSMENT SCHEME.<\/span>
\nDelattre IK1<\/sup>, Coucke W1<\/sup>, Soumali R1<\/sup>, Van de Walle P1<\/sup>, Wallemacq P2<\/sup>. 1<\/sup>Quality of Medical Laboratories, Scientific Institute of Public Health, Belgium. 2<\/sup>Laboratory of Toxicology and Therapeutic Drug Monitoring, Universit\u00e9 catholique de Louvain, Saint-Luc Hospital, Belgium.<\/span><\/p>\n

ASSESSMENT OF THERAPEUTIC GUIDELINE ADHERENCE FOR VANCOMYCIN USE IN NEONATES<\/span>
\nFirth, S.D.<\/span>1<\/sup>, Yakub, S.Y.1<\/sup>, Sherwin, C.M.T.1<\/sup>, Korgenski, E.K.2<\/sup>, Constance, J.E.1<\/sup>, Balch, A.1<\/sup>, Spigarelli, M.G1<\/sup>. 1<\/sup>Dept. of Pediatrics, Div. of Clinical Pharmacology, University of Utah. 2<\/sup>Intermountain Healthcare, Pediatric Clinical Program, University of Utah.<\/span><\/p>\n

STABILITY OF OLANZAPINE, N<\/em>-DESMETHYLOLANZAPINE (NOROLANZAPINE) AND 2-HYDROXYMETHYLOLANZAPINE IN BIOLOGICAL SAMPLES.<\/span>
\nHandley SA<\/span>, Flanagan RJ. Toxicology Unit, King\u2019s College Hospital, London, UK.<\/span><\/p>\n

PLASMA OLANZAPINE, N<\/em>-DESMETHYLOLANZAPINE (NOROLANZAPINE) AND 2-HYDROXYMETHYLOLANZAPINE CONCENTRATIONS IN PATIENTS PRESCRIBED OLANZAPINE.<\/span>
\nHandley SA<\/span>, Flanagan RJ. Toxicology Unit, King\u2019s College Hospital, London, UK.<\/span><\/p>\n

FATAL POISONING, ANTIPSYCHOTIC DRUGS, ENGLAND AND WALES, 2000\u20132011.<\/span>
\nHandley SA<\/span>, Flanagan RJ. Toxicology Unit, King\u2019s College Hospital, London, UK.<\/span><\/p>\n

EFFECT OF AGE AND GENDER ON CALCINEURIN INHIBITOR DRUG LEVELS DURING THE FIRST YEAR POST KIDNEY TRANSPLANTATION.<\/span>
\nTurolo S<\/span>1<\/sup>, Tirelli A2<\/sup>, Ghio L1<\/sup>, Belingheri M1<\/sup>, Ferraresso M3<\/sup>, Torresani E2<\/sup>, Edefonti A1<\/sup>. 1<\/sup>Pediatric Nephrology Unit, Ospedale Maggiore Policlinico Foundation, IRCCS, Milan, Italy; 2<\/sup>Laboratory of Clinical Pathology, Ospedale Maggiore Policlinico Foundation, IRCCS, Milan, Italy; 3<\/sup>Department of Clinical Sciences and Community Health, University of Milan Medical School, Milan, Italy.<\/span><\/p>\n

DETECTION OF in utero<\/em> DRUG EXPOSURE USING UMBILICAL CORD TISSUE AND LIQUID CHROMATOGRAPHY TIME-OF-FLIGHT MASS SPECTROMETRY (TOF).<\/span>
\nMarin S.J.<\/span>1<\/sup>, Metcalf A2<\/sup>, McMillin G.A.2,3<\/sup>. 1<\/sup>ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT. 2<\/sup>ARUP Laboratories, Inc., Salt Lake City, UT. 3<\/sup>Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT.<\/span><\/p>\n

CROSS VALIDATION OF THE THERMO FISHER QMS EVEROLIMUS THERAPEUTIC DRUG MONITORING ASSAY RUN ON FOUR DIFFERENT IMMUNOASSAY ANALYZER PLATFORMS WITH TEN GLOBAL LC-MS\/MS LABORATORIES.<\/span>
\nChristians, U<\/span>1<\/sup>, Schniedewind, B, Billaud, E<\/span>2<\/sup>, Poinsignon, V2<\/sup>. 1<\/sup>iC42 Clinical Research & Development, University of Colorado, Aurora, CO, USA; 2<\/sup>Universit\u00e9 Paris Descartes M\u00e9decine, HEGP Pharmacologie, Paris, France.<\/span><\/p>\n

CROSS-VALIDATION OF EVEROLIMUS LC-MS\/MS AND THERMO FISHER QMS THERAPEUTIC DRUG MONITORING ASSAYS \u2013 THE ZORTRACKER CROSS-VALIDATION AND TDM SUPPORT PROGRAM.<\/span>
\nMeyer EJ1<\/sup>, Schniedewind B2<\/sup>, Boucher R2<\/sup>, Johnson-Davis K.L.3<\/sup>, Galinkin J.L.2,4<\/sup>, Christians U<\/span>2<\/sup>. 1<\/sup>Novartis Pharmaceutical Corp., East Hannover, NJ. USA; 2<\/sup>iC42 Clinical Research & Development, University of Colorado, Aurora, CO, USA; 3<\/sup>University of Utah\/ARUP Laboratories, Salt Lake City, UT, USA; 4<\/sup>CPC Clinical Research, Aurora, CO, USA.<\/span><\/p>\n

THERAPEUTIC DRUG MONITORING OF PSYCHOTROPIC DRUGS IN CHINA: A NATION-WIDE SURVEY.<\/span>
\nWei Guo1<\/sup>, Gui-xin Guo1<\/sup>, Chuan Sun1<\/sup>, Jun Zhang1<\/sup>, Zhang Rong1<\/sup>, Jing He1<\/sup>, Zuo-li Sun1<\/sup>, Fang Yan1<\/sup>, Yi-lang Tang1,2<\/sup>, Chuan-yue Wang1<\/sup>, Wen-biao Li,1*<\/sup>. 1<\/sup>Laboratory of Clinical Psychopharmacology, Beijing Key Lab of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing 100088, China. 2<\/sup>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia 30322, USA.<\/span><\/p>\n

POPULATION PHARMACOKINETICS (popPK) OF CAPECITABINE IN ELDERLY PATIENTS WITH COLORECTAL OR BREAST CANCER.<\/span>
\n Z. Daher Abdi1,2<\/sup>, S. Lavau-Denes3<\/sup>, F.L. Sauvage 1,5<\/sup>, S.Urien4<\/sup>, J. Martin3<\/sup>, S. Leobon3<\/sup>, Jb Woillard<\/span>1, 2<\/sup>, P.Marquet1, 2,5<\/sup>, A. Rousseau1, 2<\/sup>, N. Tubiana-Mathieu3<\/sup>. 1<\/sup>Inserm, UMR-S850, Limoges, F-87025, France; 2<\/sup>Univ Limoges, F-87025, France; 3<\/sup>CHU Limoges, Service oncologie m\u00e9dicale, Limoges, F-87042, France ; 4<\/sup>EA 3620, Universit\u00e9 Paris Descartes, Sorbonne Paris Cit\u00e9, France; 5<\/sup>CHU Limoges, pharmacologie, toxicologie et pharmacovigilance, Limoges, F-87042, France.<\/span><\/p>\n

EFFECTS OF ENTERAL NUTRITION ON THE ABSORPTION OF PHENYTOIN IN RATS.<\/span>
\nUrashima Y<\/span>12<\/sup>, Suzuki K2<\/sup>, Kurachi K2<\/sup>, Nishihara M2<\/sup>, Katsumata T2<\/sup>, Tanaka K3<\/sup>, Myotoku M1<\/sup>, Hirotani Y1<\/sup>. 1<\/sup>Laboratory of Clinical Pharmaceutics, Faculty of Pharmacy, Osaka Ohtani University, 3-11-1 Nishikiorikita Tondabayashi Osaka 584-8540, Japan. 2<\/sup>Department of Pharmacy, Osaka Medical College Hospital, 2-7 Daigakumachi Takatsuki Osaka 569-8686, Japan. 3<\/sup>Shirasagi Hospital, 7-11-23 Kumata Higashisumiyoshi-ku Osaka 546-0002, Japan.<\/span><\/p>\n

INCREASED VANCOMYCIN DOSE SHOULD BE CONSIDERED FOR SEPTIC PATIENTS WITHOUT RENAL DYSFUNCTION: IMPORTANCE OF TDM-BASED DOSE ADJUSTMENT IN AN INTENSIVE CARE UNIT.<\/span>
\nYuko Shimamoto, BS<\/span>1,2<\/sup>, Tsuyoshi Fukuda, PhD3<\/sup>, Kazuhiko Tanaka, MD4<\/sup>, Katsuya Komori, BS2<\/sup>, Daikai Sadamitsu, MD5<\/sup>. 1<\/sup>Department of Pharmacy, National Cerebral and Cardiovascular Center, Osaka, Japan; 2<\/sup>Department of Pharmacy, National Hospital Organization Osaka National Hospital, Osaka, Japan; 3<\/sup>Division of Clinical Pharmacology, Cincinnati Children\u2019s Hospital Medical Center & Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA; 4<\/sup>Kidney Center, Shirasagi Hospital, Osaka, Japan; 5<\/sup>Department of Traumatology & Critical Care Medical Center, National Hospital Organization Osaka National Hospital, Osaka, Japan.<\/span><\/p>\n

1500-1600 WEDNESDAY AFTERNOON<\/span><\/p>\n

MEDICATION EXPOSURES DURING PREGNANCY AND BREASTFEEDING.<\/span>
\nGreen, A<\/span>1<\/sup>, Campbell, S.C.1<\/sup>, Thomas, K2<\/sup>, Sherwin, C.M.T.1<\/sup>, Spigarelli, M.G.1<\/sup>. 1<\/sup>Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah, USA. 2<\/sup>Utah Poison Control Center, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA.<\/span>.<\/p>\n

FEASIBILITY OF FOLLOWING UP GAMMA-HYDROXYBUTYRIC ACID CONCENTRATIONS IN SODIUM OXYBATE (Xyrem\u00ae)-TREATED NARCOLEPTIC PATIENTS USING DRIED BLOOD SPOT SAMPLING AT HOME: AN EXPLORATORY STUDY.<\/span>
\nIngels AS<\/span>1*<\/sup>, Hertegonne K2<\/sup>, Lambert W 1<\/sup>, Stove C1<\/sup>. 1<\/sup>Laboratory of Toxicology, Ghent University, Harelbekestraat 72, 9000 Ghent, Belgium; 2<\/sup>Department for Respiratory Diseases, Center for Sleep Disorders, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium; *<\/sup>Current address: Federal Public Service Justice, National Institute of Criminalistics and Criminology, Vilvoordsesteenweg 100, 1120 Brussels, Belgium. Email:christophe.stove@ugent.be<\/a>.<\/span><\/p>\n

DEVELOPMENT OF LIMITED SAMPLING STRATEGY FOR MYCOPHENOLIC ACID: INFLUENCE OF POST-TRANSPLANT PERIOD AND SECOND PEAK.<\/span>
\nChaabane A1<\/sup>, Ben Fredj N1<\/sup>, Chadly Z1<\/sup>, Hammouda M2<\/sup>, El May M2<\/sup>, Boughattas NA1<\/sup>, Skhiri H2<\/sup>, Aouam K1<\/sup>. 1<\/sup>Pharmacology Laboratory. Faculty of Medicine of Monastir. University of Monastir. 2<\/sup>Nephrology Department. University Hospital of Monastir. University of Monastir.<\/span><\/p>\n

DEVELOPMENT OF LIMITED SAMPLING STRATEGIES FOR TACROLIMUS ACCORDING TO THE POST-TRANSPLANT PERIOD.<\/span>
\nAouam K1<\/sup>, Chadly Z1<\/sup>, Chaabane A1<\/sup>, Ben Fredj N1<\/sup>, Hammouda M2<\/sup>, El May M2<\/sup>, Boughattas NA1<\/sup>, Skhiri H2<\/sup>.1<\/sup>Pharmacology Laboratory. Faculty of Medicine of Monastir. University of Monastir. 2<\/sup>Nephrology Department. University Hospital of Monastir. University of Monastir.<\/span><\/p>\n

EFFECT OF ANGIOTENSIN II RECEPTOR BLOCKERS ON FORMATION OF EPOXYEICOSATRIENOIC ACIDS FROM ARACHIDONIC ACID VIA P450(CYP)2C9 AND CYP2C8.<\/span>
\nSenda A<\/span>1<\/sup>, Toda T1<\/sup>, Hayakawa T1<\/sup>, Inotsume N1<\/sup>, Rane A2<\/sup>, Eliasson E2<\/sup>. 1<\/sup>Hokkaido Pharmaceutical University School of Pharmacy; 2<\/sup>Karolinska Institutet.<\/span><\/p>\n

THE EFFECTS OF OCCUPATIONAL ENVIRONMENT EXPOSURE ON ORGAN FUNCTIONS, EXPRESSION OF CYTOKERATIN \u2013 19 FRAGMENTS (CYFRA 21 -1 PROTEIN) AND RISK OF LUNG CANCER IN SOME WELDERS.<\/span>
\nBosun Banjoko<\/span>1*<\/sup>, Olusoji Ige2<\/sup>, Olufunso Olorunsogo3<\/sup>. 1<\/sup>Department of Chemical Pathology, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria. 2<\/sup>Department of Medicine, College of Medicine, University of Ibadan, Ibadan, Nigeria. 3<\/sup>Department of Biochemistry, College of Medicine, University of Ibadan, Ibadan, Nigeria. *<\/sup>Correspondence: bosunbanjoko@yahoo.com<\/a><\/span><\/p>\n

PUBLISHED THERAPEUTIC DRUG MONITORING STUDIES: WHO IS SUPPORTING RESEARCH?<\/span>
\nStockmann, C.<\/span>, Sherwin, C.M.T., Spigarelli, M.G. Department of Pediatrics, Division of Clinical Pharmacology, University of Utah.<\/span><\/span><\/p>\n

EFFECT OF IMMUNOSUPPRESSION WITH TACROLIMUS (Tac), MYCOPHENOLATE SODIUM (MPS), AND STEROIDS ON INFLAMMATION AND OXIDATIVE STRESS IN KIDNEY TRANSPLANT RECIPIENTS (KTR) WITH METABOLIC SYNDROME (MS).<\/span>
\nWieland E<\/span>, H\u00e4fner S, Kabakchiev M, Shipkova M, Effenberger-Klein A, Olbricht CJ, Lobmann R. Klinikum Stuttgart, Germany<\/span><\/p>\n

STUDY OF LEUCIN-RICH REPEAT KINASE 2 (LRRK2) G2019S MUTATION IN EGYPTIAN PATIENTS WITH PARKINSONISM<\/span>
\nEL Desoky ES<\/span>1<\/sup>*, Khedr EM2<\/sup>*, Khalil MS3<\/sup>*, and Gasser T4<\/sup>. 1<\/sup>Pharmacology, 2<\/sup>neurology and 3<\/sup>clinical pathology departments, Assiut Faculty of Medicine and University Hospital , Assiut, Egypt*. 4<\/sup>Hertie Institute for Clinical Brain Research Department of Neurodegenerative Diseases, T\u00fcbingen, Germany.<\/span><\/p>\n

CYP2D6 AND ADJUVANT TAMOXIFEN: POSSIBLE DIFFERENCES IN OUTCOME FOR PRE- AND POSTMENOPAUSAL PATIENTS.<\/span>
\nMargolin S1<\/sup>, Lindh JD2<\/sup>, Thor\u00e9n L1<\/sup>, Xie H-J1<\/sup>, Koukel L2<\/sup>, Dahl M-L2<\/sup>, Eliasson E<\/span>2<\/sup>. Karolinska Institutet, 1<\/sup>Department of Oncology & Pathology, 2<\/sup>Department of Laboratory Medicine, Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden.<\/span>
\n
\nNEW ANALYSIS METHOD FOR PHOSPHATIDYLETHANOL 16:0\/18:1 FROM WHOLE BLOOD BY UPLC-MS\/MS.<\/span>
\nShafaati M1<\/sup>, Hedman E<\/span>1<\/sup>, Helander A2<\/sup>, Beck O1<\/sup>. 1<\/sup>Department of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden. 2<\/sup>Department of Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden.<\/span>
\n
\nEARLY TACROLIMUS DOSING IN PEDIATRIC LIVER TRANSPLANTATION DEPENDS ON RECIPIENT CYP3A5 AND ABCB1 (OR MDR1) GENOTYPES: EXPERIENCE IN LIVING DONOR RECIPIENTS.<\/span>
\nGuy-Viterbo V<\/span>1<\/sup>, Panain N1<\/sup>, Janssen M2<\/sup>, Elens L1<\/sup>, Reding R2<\/sup>, Haufroid V1<\/sup>, Wallemacq P1<\/sup>. 1<\/sup>Louvain center for Toxicology & Applied Pharmacology (LTAP), Universit\u00e9 Catholique de Louvain, Brussels, Belgium. 2<\/sup>Pediatric surgery and transplantation unit, Cliniques Universitaires St-Luc, Universit\u00e9 Catholique de Louvain, Brussels, Belgium.<\/span>
\n
\nUSEFULNESS OF ONE-POINT PLASMA SN-38G\/SN-38 CONCENTRATION RATIOS AS A SUBSTITUTE FOR UGT1A1 GENETIC INFORMATION AFTER IRINOTECAN ADMINISTRATION<\/span>
\nH. Takada<\/span>1<\/sup>, K. Hirose1<\/sup>, K. Yamashita1<\/sup>, N. Kaneda1<\/sup>, K. Fukami1<\/sup>, E. Maruo1<\/sup>, M. Kitamura1<\/sup>, J. Hasegawa2<\/sup>, Y. Maeda1<\/sup>
\n1<\/sup>Department of Pharmacy, Osaka Rosai Hospital. 2<\/sup>Department of Surgery, Osaka Rosai Hospital.
\n
\nPOPULATION PHARMACODYNAMIC ANALYSIS OF HMG-COA REDUCTASE INHIBITORS (STATINS) IN JAPANESE ADULT PATIENTS BASED ON THE IN-HOSPITAL MEDICAL RECORDS<\/span>
\nNomura H<\/span>1<\/sup>, Kakara M2<\/sup>, Yamasaki T2<\/sup>, Fukae M2<\/sup>, Hirota T2<\/sup>, Hirakawa M1<\/sup>, Ieiri I2<\/sup>. 1<\/sup>Department of Hospital Pharmacy, Fukuoka Tokushukai Medical Center, Fukuoka, Japan; 2<\/sup>Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
\n
\nPOPULATION PHARMACOKINETICS AND BAYESIAN ESTIMATION OF MELPHALAN CONCENTRATIONS IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION.<\/span>
\nMizuno K<\/span>1<\/sup>, Dong M1<\/sup>, Fukuda T1,2<\/sup>, Anaissie E.J.3<\/sup>, Vinks A.A.1,2<\/sup>. 1<\/sup>Division of Clinical Pharmacology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA. 2<\/sup>Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH, USA. 3<\/sup>University of Cincinnati Cancer Institute, College of Medicine, University of Cincinnati, Cincinnati, OH, USA.
\n
\nUSEFULNESS OF JAPANESE EGFR IN PHARMACOKINETIC ANALYSIS OF AMIKACIN.<\/span>
\nShinozaki K1,3<\/sup>, Yamamoto M1<\/sup>, Tanaka J1<\/sup>, Kobayashi Y2<\/sup>, Saito M2<\/sup>. 1<\/sup>Pharmacokinetic Laboratory, Department of Clinical Pharmacy, Center for Clinical Pharmacy and Sciences, School of Pharmacy, Kitasato University, Tokyo, Japan. 2<\/sup>Department of Pharmacy, Kitasato Institute Hospital, Tokyo, Japan. 3<\/sup>Division of TDM, Kitasato Institute Hospital, Tokyo, Japan.
\n
\nIMPACT OF POR<\/em>*28 ON THE PHARMACOKINETICS OF TACROLIMUS AND CYCLOSPORINE A IN RENAL TRANSPLANT PATIENTS.<\/span>
\nLaure Elens1,3<\/sup>, Dennis A. Hesselink2<\/sup>, Rachida Bouamar4<\/sup>, Klemens Budde5<\/sup>, Johannes W. de Fijter6<\/sup>, Dirk R.J. Kuypers7<\/sup>, Vincent Haufroid3<\/sup>, Teun van Gelder2,4<\/sup>, Ron H.N. van Schaik1<\/sup>. 1<\/sup>Departments of Clinical Chemistry, 2<\/sup>Internal Medicine, 4<\/sup>Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands, 3<\/sup>Louvain centre for Toxicology and Applied Pharmacology (LTAP), Universit\u00e9 catholique de Louvain, Brussels, Belgium, 5<\/sup>Dept. Nephrology, Charite University, Berlin, Germany, 6<\/sup>Dept. Nephrology, Leiden University Medical Centre, Leiden, The Netherlands, 7<\/sup>Dept. Nephrology, University of Leuven, Leuven, Belgium.<\/span>
\n
\nA POTENTIAL PROTEOMIC BIOMARKER OF LOVASTATIN-INDUCED MACROPHAGE TOXICITY.<\/span>
\nL. Zhang<\/span>, X. Zhou, and A. Zhou. Cleveland State University, Cleveland, OH 44115.<\/span>
\n
\nENDOXIFEN LEVELS ASSOCIATED TO CYP2D6 PHENOTYPE.<\/span>
\nAntunes MV<\/span>, Santos TV, Andreolla H, Rosa DD, Linden R. Universidade Feevale, Novo Hamburgo \u2013 RS, Brazil.<\/span>
\n
\nCYP2D6 PHENOTYPING BY HPLC-FL DETERMINATION OF DEXTROMETHORPHAN AND DEXTRORPHAN IN HUMAN PLASMA.<\/span>
\nAntunes MV<\/span>, Santos TV, Andreolla H, Rosa DD, Linden R. Universidade Feevale, Novo Hamburgo \u2013 RS, Brasil.<\/span>
\n
\nTHERAPEUTIC POTENTIAL OF THE NAT2<\/em> GENOTYPE-GUIDED DOSING STRATIFICATION OF ISONIAZID IN CHEMOTHERAPY FOR TUBERCULOSIS.<\/span>
\nOhno M<\/span>1,2<\/sup>, Azuma J1,2<\/sup>, Yokota S3<\/sup>, and Pharmacogenetics-based tuberculosis therapy research group. 1<\/sup>Hyogo University of Health Sciences. 2<\/sup>Graduate School of Pharmaceutical Sciences, Osaka University. 3<\/sup>National Hospital Organization Toneyama National Hospital, Japan.<\/span>
\n
\nSUICIDE AND HOMICIDE BY Para-phenylenediamine POISONING IN UPPER EGYPT.<\/span>
\nMaha A. Hilal1<\/sup>, Khaled M. Mohamed2<\/sup>, Nady S. Aly2<\/sup>. 1<\/sup>Forensic Medicine and Clinical Toxicology Department, Faculty of Medicine, Sohag University, Egypt. 2<\/sup>Assiut Chemical Laboratory, Medico-Legal Department, Ministry of Justice, Egypt.
\n
\nA STUDY ON THE ASSOCIATION OF HLA-B*1502 AND SEVERE CUTANEOUS ADVERSE DRUG REACTIONS INDUCED BY AROMATIC AMINE ANTI-EPILEPTIC DRUGS IN INDIAN PATIENTS: AN INTERIM REPORT.<\/span>
\nNaik GS<\/span>1<\/sup>, Vijayakumar TS2<\/sup>, Krishnan M2<\/sup>, Mathew SK1<\/sup>, Fleming DH1<\/sup>, Thomas M3<\/sup>, George R4<\/sup>.1<\/sup>Department of Pharmacology and Clinical Pharmacology, Christian Medical College, Vellore, 632 004, Tamil Nadu, India. 2<\/sup>Molecular Laboratory, Department of Nephrology, Christian Medical College, Vellore, 632 004, Tamil Nadu, India. 3<\/sup>Department of Neurology, Christian Medical College, Vellore, 632 004, Tamil Nadu, India. 4<\/sup>Department of Dermatology, Christian Medical College, Vellore, 632 004, Tamil Nadu, India.
\n
\nCONVERSION FROM TWICE-DAILY TO ONCE-DAILY TACROLIMUS FORMULATION DOES NOT REDUCE INTRA-PATIENT VARIABILITY IN TACROLIMUS EXPOSURE<\/span>
\nShuker N<\/span>1<\/sup>, van Gelder T1,2<\/sup>, Cadogan M2<\/sup>, Weimar W2<\/sup>, Hesselink D.A.2<\/sup>. Departments of 1<\/sup>Hospital Pharmacy, Clinical Pharmacology Unit and 2<\/sup>Internal Medicine, Division of Nephrology and Renal Transplantation, Erasmus MC, University Medical Center Rotterdam, the Netherlands.
\n
\nIMPACT OF EVEROLIMUS ON IL-12, IL10, IL17 AND IFN-γ PRODUCTION: BALANCE BETWEEN EFFECTOR AND INFLAMMATORY RESPONSES IN LIVER TRANSPLANT RECIPIENTS.<\/span>
\nO Mill\u00e1n<\/span>1<\/sup>, Z. Mari\u00f1o2<\/sup>, G. Crespo2<\/sup>, M. Navasa2<\/sup>, M. Brunet1<\/sup>. 1<\/sup>Pharmacology and Toxicology Laboratory (CDB), CIBERehd, IDIBAPS, Hospital Cl\u00ednic de Barcelona. 2<\/sup>Liver Transplant Unit, CIBERehd, IDIBAPS; Hospital Cl\u00ednic de Barcelona.<\/span>
\n
\nINFLUENCE OF GENETIC POLYMORPHISMS IN PATIENTS TREATED WITH NON-STANDARD TACROLIMUS DOSE REQUIREMENTS.<\/span>
\nOuteda-Mac\u00edas M<\/span>, Salvador-Garrido P, Mart\u00ednez-L\u00f3pez LM, Cachafeiro-Pin AI, Mart\u00edn-Herranz I. Pharmacy Service, University Hospital of A Coru\u00f1a. Xerencia de Xesti\u00f3n Integrada A Coru\u00f1a. A Coru\u00f1a, Spain.<\/span>
\n
\nROLE OF CYP2C9 AND VKORC1 POLYMORPHISMS IN PATIENTS WITH HYPERSENSITIVITY TO ACENOCOUMAROL.<\/span>
\nOuteda-Mac\u00edas M<\/span>, Salvador-Garrido P, Mart\u00ednez-L\u00f3pez LM, S\u00e1nchez-Parada L, Mart\u00edn-Herranz I. Pharmacy Service, University Hospital of A Coru\u00f1a. Xerencia de Xesti\u00f3n Integrada A Coru\u00f1a. A Coru\u00f1a, Spain.<\/span>
\n
\nDETECTION OF OUTLIERS AND ACCURACY OF PHARMACOKINETIC PARAMETER ESTIMATION USING PARAMETRIC AND NON PARAMETRIC POPULATION MODELING APPROACHES.<\/span>
\nCaceres Guido P.1<\/sup>, Neely M. N.2<\/sup>, Niselman V.3<\/sup>, Schaiquevich P.1,4<\/sup>. 1<\/sup>Clinical Pharmacokinetics Unit, Hospital de Pediatria JP Garrahan, Buenos Aires, Argentina. 2<\/sup>Laboratory of Applied Pharmacokinetics, University of Southern California and Children\u2019s Hospital Los Angeles, Los Angeles, CA, United States of America. 3<\/sup>Mathematics, Faculty of Pharmacy and Biochemistry, University of Buenos Aires. 4<\/sup>CONICET.<\/span>
\n
\nCLINICAL PHARMACOKINETICS OF MELPHALAN AFTER SUPER-SELECTIVE OPHTHALMIC ARTERY INFUSION IN RETINOBLASTOMA PATIENTS.<\/span>
\nSchaiquevich P1,5<\/sup>, Taich P1<\/sup>, Buitrago E1<\/sup>, Ceciliano A2<\/sup>, Villasante F2<\/sup>, Fandi\u00f1o A3<\/sup>, Chantada G4<\/sup>. 1<\/sup>Clinical Pharmacokinetics Unit, Hospital de Pediatria JP Garrahan. 2<\/sup> Swiss Argentine Clinic and Maternity. 3,4<\/sup>Services of Ophtahlmology and Hematology-Oncology, Hospital JP Garrahan, Argentina. 5<\/sup>CONICET.<\/span>
\n
\nGENETIC DATABASES AND THEIR PITFALLS: AN EXAMPLE RELATED TO PHARMACOGENETICS.<\/span>
\nPouch\u00e9 L1,2,3<\/sup>, Avcu K3<\/sup>, Esperon P4<\/sup>, Noceti O1,2,4<\/sup>, Marquet P1,2,3<\/sup>, Picard N1,2,3<\/sup>. 1<\/sup>Inserm, UMR S-850, Limoges, France. 2<\/sup>Univ. Limoges; 3<\/sup>CHU Limoges, Department of Pharmacology and Toxicology, 4<\/sup>Molecular Biology Unit, Clinical Biochemistry Department , Faculty of Chemistry, University of the Republic, Montevideo, Uruguay.
\n
\nSIMULTANEOUS DETERMINATION OF LAMOTRIGINE, 10-HYDROXY-CARBAMAZEPINE, PHENOBARBITAL, CARBAMAZEPINE-10,11-EPOXIDE, PHENYTOIN AND CARBAMAZEPINE IN DRIED BLOOD SPOTS BY HPLC-DAD.<\/span>
\nLima GMS, Rhoden L, Silva CA, Rama C, Linden, R<\/span>. Universidade Feevale, Novo Hamburgo, Brazil.
\n
\nROPIVACAINE CONCENTRATIONS (TOTAL AND UNBOUND) FOLLOWING TRANSVERSE ABDOMINIS PLANE (TAP) BLOCK FOR ANALGESIA FOLLOWING ABDOMINAL SURGERY \u2013 A PILOT STUDY.<\/span>
\nMorris RG<\/span>1,2<\/sup>, Kumar S3<\/sup>, Watts R3<\/sup>, Rao V3<\/sup>, Westley IS1<\/sup>. 1<\/sup>Department of Cardiol & Clin Pharmacol, The Queen Elizabeth Hospital, Woodville, SA; 2<\/sup>Discipline of Pharmacol, The University of Adelaide. Adelaide, SA; 3<\/sup>Department of Anaesthesia, The Queen Elizabeth Hospital, Woodville, SA.<\/span>
\n
\nTHIOPURINE METHYLTRANSFERASE PHARMACOGENOMIC TESTING: KNOWN BUT INFREQUENTLY DONE.<\/span>
\nCampbell, S.C.<\/span>1<\/sup>, McMillin, G2<\/sup>, Sherwin, C.M.T.1<\/sup>, Spigarelli, M.G.1<\/sup>. 1<\/sup>Department of Pediatrics, Division of Clinical Pharmacology, University of Utah. 2<\/sup>Department of Pathology and ARUP Laboratories, University of Utah.<\/span>
\n
\nTHE EFFECT OF AGE ON A BIOMARKER OF ACETAMINOPHEN-INDUCED HEPATOTOXICITY.<\/span>
\nCook SF<\/span>1,2<\/sup>, Parker AD1<\/sup>, Hathaway LB2<\/sup>, McGill LD3<\/sup>, Franklin MR2<\/sup>, Wilkins DG1,2<\/sup>, Rollins DE1,2<\/sup>. 1<\/sup>Center for Human Toxicology, University of Utah, Salt Lake City, UT. 2<\/sup>Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT. 3<\/sup>Associated Regional and University Pathologists, Inc., Salt Lake City, UT.<\/span>
\n
\nPHARMACOKINETICS OF MORPHINE DURING PATIENT-CONTROLLED ANALGESIA (PCA) IN POST-OPERATIVE PAIN RELIEF.<\/span>
\nDe Gregori S<\/span>1<\/sup>, Niebel T2<\/sup>, Bugada D2<\/sup>, Regazzi M1<\/sup>. 1<\/sup>Clinical and Experimental Pharmacokinetics Unit, Fondazione IRCCS Policlinico San Matteo, Pavia. 2<\/sup>Pain Therapy Service, Fondazione IRCCS Policlinico San Matteo, Pavia.
\n
\nINVESTIGATION OF QUETIAPINE PHARMACOKINETICS AND ITS CORRELATION WITH CYP3A5 OR MDR1 POLYMORPHISMS: A POPULATION PHARMACOKINETIC APPROACH.<\/span>
\nSireen Shilbayeh, PhD1<\/sup>, Melhem, PhD2<\/sup>, Rawan Zmeili, MSc3<\/sup>. 1<\/sup>Clinical Pharmacy Department, Pharmacy College, Princess Nora University, Riyadh, Kingdom of Saudi Arabia. 2<\/sup>Institute for Clinical Pharmacodynamics, Latham, NY, USA. 3<\/sup>ICU Clinical Pharmacy Services, King Saud Medical City, Riyadh, Kingdom of Saudi Arabia.<\/span>
\n
\nPOPULATION PHARMACOKINETICS OF CAFFEINE IN NEONATES TO IMPROVE THERAPEUTIC RANGE ATTAINMENT.<\/span>
\nYu, T.<\/span>, Sherwin, C.M.T., Balch, A., Spigarelli, M.G. Department of Pediatrics, Div. of Clinical Pharmacology, University of Utah.<\/span>
\n
\nCHARACTERISTICS AND TRENDS OF VANCOMYCIN CLINICAL TRIALS REGISTERED IN THE UNITED STATES FROM 1997-2012.<\/span>
\nYu, T.<\/span>, Stockmann C., Balch A., Sherwin C.M.T., Spigarelli M.G. Division of Clinical Pharmacology, Department of Pediatrics, University of Utah.<\/span>
\n
\nTHE ELEVATION OF PLASMA CREATINE PHOSPHOKINASE LEVEL INDUCED BY DAPTOMYCIN: A CASE REPORT.<\/span>
\nTomoyuki Yamada<\/span>1,2<\/sup>, Kaoru Suzuki1<\/sup>, Yukimasa Ooi2,3<\/sup>, Fumiko Kawanishi2<\/sup>, Yuriko Shibata2<\/sup>, Takashi Nakano2,4<\/sup>, Masami Nishihara1<\/sup>, Takahiro Katsumata1<\/sup>, Akira Ukimura2,3<\/sup>. 1<\/sup>Department of pharmacy, Osaka Medical College Hospital.2<\/sup>Infection control center, Osaka Medical College Hospital. 3<\/sup>Department of general internal medicine, Osaka Medical College. 4<\/sup>Department of microbiology and infection control, Osaka Medical College.<\/span>
\n
\nPOTENTIAL APPLICATION OF GAMMA-HYDROXYBUTYRIC ACID GLUCURONIDE IN URINE AS A BIOMARKER FOR GHB INTOXICATION.<\/span>
\nBreindahl T<\/span>1<\/sup>, Eriksen K.K.2<\/sup>, M\u00f8ller K3<\/sup>, Skanning P.G 3<\/sup>. 1<\/sup>Department of Clinical Biochemistry, Vendsyssel Hospital, Aalborg University, Denmark. 2<\/sup>Department of Clinical Biochemistry, Bispebjerg Hospital, Denmark. 3<\/sup>Department of Anesthesiology Z, Bispebjerg Hospital, Denmark.<\/span>
\n
\nCAUSES OF VARIABILITY IN DETERIORATION OF RENAL FUNCTION AMONG PEDIATRIC LIVER TRANSPLANT RECIPIENTS RECEIVING TACROLIMUS.<\/span>
\nGijsen V.M.G.J.<\/span>1,2<\/sup>, Hesselink D. A.3<\/sup>, \u2018t Jong G.W.2<\/sup>, van Schaik R.H.N.4<\/sup>, Ng V.5<\/sup>, Grant D.6<\/sup>, Feroz Zada Y.7<\/sup>, Nasserinejad K.8<\/sup>, van Rosmalen J.8<\/sup>, Verjee Z.9<\/sup>, Ross C.10<\/sup>, Carleton B.10<\/sup>, Hayden M.R.11<\/sup>, Tibboel D.1<\/sup>, Dub\u00e9 M-P7,12<\/sup>, Koren G.2,13<\/sup>, de Wildt S.N.1<\/sup>. 1<\/sup>Intensive Care and Department of Paediatric Surgery, Erasmus MC Sophia Children\u2019s Hospital, Rotterdam, the Netherlands. 2<\/sup>Division of Clinical Pharmacology and Toxicology, Hospital for Sick Children, Toronto, Ontario, Canada. 3<\/sup>Department of Internal Medicine, Division of Nephrology and Renal Transplantation, Erasmus MC, Rotterdam, the Netherlands. 4<\/sup>Department of Clinical Chemistry, Erasmus MC, Rotterdam, the Netherlands. 5<\/sup>Division of Gastroenterology and Nutrition, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada. 6<\/sup>Multi-Organ Transplant Program, University of Toronto, Toronto, Ontario, Canada. 7<\/sup>Universit\u00e9 de Montr\u00e9al, Department of Medicine, Montr\u00e9al, Quebec, Canada. 8<\/sup>Department of Biostatistics, Erasmus MC, Rotterdam, the Netherlands. 9<\/sup>Department of Pediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada and Assistant Professor, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. 10<\/sup>Department of Paediatrics, Division of Translational Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada. 11<\/sup>Department of Medical Genetics, Faculty of Medicine, Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada. 12<\/sup>Montr\u00e9al Heart Institute Research Centre, Montr\u00e9al, Quebec, Canada. 13<\/sup>Ivey Chair in Molecular Toxicology, Department of Medicine, University of Western Ontario, London, ON, Canada.<\/span>
\n
\nGENETIC VARIATION DOES NOT INFLUENCE RENAL FUNCTION FOLLOWING PEDIATRIC KIDNEY TRANSPLANTATION RECEIVING TACROLIMUS.<\/span>
\nGijsen V.M.G.J.<\/span>1,2<\/sup>, Hesselink D.A.3<\/sup>, Ross C.4<\/sup>, Dub\u00e9 M-P.5,6<\/sup>, van Schaik R.H.N.7<\/sup>, Van Gelder T.3,8<\/sup>, Cransberg K.9<\/sup>, \u2018t Jong G.W.2<\/sup>, Feroz-Zada Y.5<\/sup>, Nasserinejad K.10<\/sup>, van Rosmalen J.10<\/sup>, Hebert D.11<\/sup>, Grant D.12<\/sup>, Verjee Z.13<\/sup>, Carlton B.4<\/sup>, Hayden M.R.14<\/sup>, Tibboel D.1<\/sup>, de Wildt S.N.1<\/sup>, Koren G.2,15<\/sup>. 1<\/sup> Intensive Care and Department of Pediatric Surgery, Erasmus MC Sophia Children\u2019s Hospital, Rotterdam, the Netherlands. 2<\/sup>Division of Clinical Pharmacology and Toxicology, Hospital for Sick Children, Toronto, Ontario, Canada. 3<\/sup>Department of Internal Medicine, Division of Nephrology and Renal Transplantation, Erasmus MC, Rotterdam, the Netherlands. 4<\/sup>Department of Pediatrics, Division of Translational Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada. 5<\/sup>Montr\u00e9al Heart Institute Research Centre, Montr\u00e9al, Quebec, Canada. 6<\/sup>Universit\u00e9 de Montr\u00e9al, Department of Medicine, Montr\u00e9al, Quebec, Canada. 7<\/sup>Department of Clinical Chemistry, Erasmus MC, Rotterdam, the Netherlands. 8<\/sup>Hospital Pharmacy, Erasmus MC, Rotterdam, the Netherlands. 9<\/sup>Department of Pediatric Nephrology, Erasmus MC Sophia Children\u2019s Hospital, Rotterdam, the Netherlands. 10<\/sup>Department of Biostatistics, Erasmus MC, Rotterdam, the Netherlands. 11<\/sup>Division of Nephrology, The Hospital for Sick Children, Toronto, Ontario, Canada. 12<\/sup>Multi-Organ Transplant Program, University of Toronto, Toronto, Ontario, Canada. 13<\/sup>Department of Laboratory Medicine and Pathobiology, The Hospital for Sick Children, Toronto, Ontario, Canada. 14<\/sup>Department of Medical Genetics, Faculty of Medicine, Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada. 15<\/sup>Ivey Chair in Molecular Toxicology, Department of Medicine, University of Western Ontario, London, ON, Canada.<\/span>
\n
\nINVESTIGATING GENETIC AND CLINICAL SOURCES OF VARIABILITY IN PREDICTING DETERIORATION OF RENAL FUNCTION AMONG PEDIATRIC HEART TRANSPLANT RECIPIENTS RECEIVING TACROLIMUS.<\/span>
\nGijsen V.M.G.J.<\/span>1,2<\/sup>, Dub\u00e9 M-P3,4<\/sup>, Hesselink D.A.5<\/sup>, Ross C.6<\/sup>, Mital S.7<\/sup>, \u2018t Jong G.W.2<\/sup>, van Schaik R.H.N8<\/sup>, Dalinghaus M.9<\/sup>, Grant D.10<\/sup>, Feroz Zada Y.4<\/sup>, Nasserinejad K.11<\/sup>, van Rosmalen J.11<\/sup>, Verjee Z.12<\/sup>, Carleton B.6<\/sup>, Hayden M.R.13<\/sup>, Tibboel D.1<\/sup>, Koren G.2,14<\/sup>, de Wildt S.N.1<\/sup>. 1<\/sup>Intensive Care and Department of Pediatric Surgery, Erasmus MC Sophia Children\u2019s Hospital, Rotterdam, the Netherlands. 2<\/sup>Division of Clinical Pharmacology and Toxicology, Hospital for Sick Children, Toronto, Ontario, Canada. 3<\/sup>Montr\u00e9al Heart Institute Research Centre, Montr\u00e9al, Quebec, Canada. 4<\/sup>Universit\u00e9 de Montr\u00e9al, Department of Medicine, Montr\u00e9al, Quebec, Canada. 5<\/sup>Department of Internal Medicine, Division of Nephrology and Renal Transplantation, Erasmus MC, Rotterdam, the Netherlands. 6<\/sup>Department of Medical Genetics, Faculty of Medicine, Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada. 7<\/sup>Division of Cardiology, Hospital for Sick Children, Toronto, Ontario, Canada. 8<\/sup>Department of Clinical Chemistry, Erasmus MC, Rotterdam, the Netherlands. 9<\/sup>Pediatric Cardiology, Erasmus MC Sophia Children\u2019s Hospital, Rotterdam, the Netherlands. 10<\/sup>Multi-Organ Transplant Program, University of Toronto, Toronto, Ontario, Canada. 11<\/sup>Department of Biostatistics, Erasmus MC, Rotterdam, the Netherlands. 12<\/sup>Department of Laboratory Medicine and Pathobiology, The Hospital for Sick Children, Toronto, Ontario, Canada. 13<\/sup>Department of Paediatrics, Division of Translational Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada. 14<\/sup>Ivey Chair in Molecular Toxicology, Department of Medicine, University of Western Ontario, London, ON, Canada.<\/span>
\n
\nHOW TO HANDLE WITH TIME-DEPENDENT METHOTREXATE ELIMINATION: A MODELING APPROACH.<\/span>
\nWoillard JB<\/span>1,2<\/sup>, Debord J1,2<\/sup>, Neely M3<\/sup>, Marquet P1,2<\/sup>, Saint-Marcoux F1,2<\/sup>. 1<\/sup>Pharmacology Department, CHU Limoges, France. 2<\/sup>INSERM UMR-S850, Univ Limoges, France. 3<\/sup>Laboratory of Applied Pharmacokinetics, University of Southern California Keck School of Medicine, Los Angeles, CA, USA. <\/span>
\n
\nSIGNIFICANT INCREASE IN PLASMA 4\u0392-HYDROXYCHOLESTEROL CONCENTRATION AS AN ENDOGENOUS MARKER OF CYP3A ACTIVITY IN PATIENTS WITH END STAGE RENAL DISEASE AFTER KIDNEY TRANSPLANTATION<\/span>
\nSuzuki Y<\/span>1<\/sup>, Itoh H1<\/sup>, Sato F2<\/sup>, Kawasaki K1<\/sup>, Sato Y1<\/sup>, Fujioka T1<\/sup>, Sato Y1<\/sup>, Ohno K3<\/sup>, Mimata H2<\/sup>, Kishino S3<\/sup>. 1<\/sup>Department of Clinical Pharmacy, Oita University Hospital, Hasama-machi, Oita 879-5593, Japan.\t2<\/sup>Department of Urology, Faculty of Medicine, Oita University, Hasama-machi, Oita 879-5593, Japan. 3<\/sup>Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Kiyose, Tokyo 204-8588, Japan.<\/span>
\n
\nPOISON CONTROL CENTER CALLS REGARDING PREGNANT AND BREASTFEEDING WOMEN.<\/span>
\nBridges, Z.M.<\/span>, Campbell, S.C., Thomas, K.C., Sherwin, C.M.T., Spigarelli, M.G. Department of Pediatrics, Division of Clinical Pharmacology, University of Utah.<\/span>
\n
\nASSESSMENT OF ABUSE DRUGS IN EMERGENCY HOSPITAL, MANSOURA UNIVERSITY, EGYPT.<\/span>
\nR.A. Mandour<\/span>1<\/sup>*, A.A. Ghanem2<\/sup>. 1<\/sup>Toxicology Unit, Emergency Hospital, Mansoura University, Egypt. 2<\/sup>Forensic Med. and Clin. Toxic. Department, Faculty of Medicine, Mansoura University, Egypt. *Correspondence: mandourraafat@yahoo.com<\/a>, 0020125260108.<\/span><\/p>\n

TPMT ALLELIC VARIANTS IN PATIENTS ON THIOPURINE THERAPY.<\/span>
\nRaghavan R.1<\/sup>, Shah S.1<\/sup>, Bhawalkar S.1<\/sup>, Desai D.2<\/sup>, Kapadia A.3<\/sup>, Almel S.3<\/sup>, Ashavaid T.F.1<\/sup>. 1<\/sup>Department of Laboratory Medicine, P.D.Hinduja National Hospital & MRC, Mumbai, India. Department of Gastroenterology, P.D.Hinduja National Hospital & MRC, Mumbai, India. 3<\/sup>Department of Oncology, P.D.Hinduja National Hospital & MRC, Mumbai, India.<\/span>
\n
\n1330-1430 THRUSDAY AFTERNOON<\/span>
\n
\nPERFORMANCE CHARACTERISTICS OF THREE ASSAYS FOR THE THERAPEUTIC DRUG MONITORING OF METHOTREXATE.<\/span>
\nSuh-Lailam B<\/span>1<\/sup>, Juenke J2<\/sup>, Thompson C3<\/sup>, Wilson L3<\/sup>, Johnson-Davis K1,2<\/sup>. 1<\/sup>Department of Pathology, University of Utah, Salt Lake City, 84112. 2<\/sup>ARUP Institute of Clinical and Experimental Pathology, Salt Lake City, Utah 84108. 3<\/sup>ARUP Laboratories, Salt Lake City, Utah 84108.<\/span>
\n
\nTHE QMS\u00ae TACROLIMUS ASSAY ON THE ROCHE COBAS\u00ae 6000 C501 ANALYZER \u2013 COMPARISON TO LCMS\/MS.<\/span>
\nShalapay C<\/span>, LeGatt D. Department of Laboratory Medicine and Pathology, University of Alberta Hospital, Alberta Health Services, Edmonton, Canada.
\n
\nDEVELOPMENT AND VALIDATION OF A MATRIX-MATCHED ASSAY TO MEASURE IODINE IN SERUM BY INDUCTIVELY COUPLED PLASMA-MASS SPECTROMETRY.<\/span>
\nHaglock C.J.<\/span>1<\/sup>, Strathmann F.G.1,2<\/sup>. 1<\/sup>ARUP Laboratories, Salt Lake City, UT; 2<\/sup>ARUP Institute for Clinical and Experimental Pathology, and Department of Pathology, University of Utah, Salt Lake City, UT.<\/span>
\n
\nPRECISION AND ACCURACY PERFORMANCE EVALUATION OF THE ELECSYS TACROLIMUS AND CYCLOSPORINE A ASSAYS.<\/span>
\nShipkova M.<\/span>1<\/sup>, Verstraete A.2<\/sup>, Wallemacq P.3<\/sup>, Vogeser M.4<\/sup>, Al\u00eca P.5<\/sup>, Widmann M.6<\/sup>, Schneider-Thauern C.6<\/sup>. 1<\/sup>Katharinenhospital Stuttgart, Germany; 2<\/sup>Gent University Hospital, Belgium; 3<\/sup>Clinique Universitaire St. Luc, Belgium; 4<\/sup>Klinikum der Universit\u00e4t M\u00fcnchen, LMU, Germany; 5<\/sup>Hospital Universitari de Bellvitge, Spain; 6<\/sup>Roche Diagnostics GmbH Mannheim, Germany.<\/span>
\n
\nMETHOD COMPARISON STUDY OF THE ELECSYS TACROLIMUS ASSAY WITH LC-MS\/MS, ABBOTT ARCHITECT AND SIEMENS DIMENSION AS COMPARATORS.<\/span>
\nWallemacq, P.<\/span>1<\/sup>, Shipkova M.2<\/sup>, Verstraete A.3<\/sup>, Vogeser M.4<\/sup>, Al\u00eda P.5<\/sup>, Schneider-Thauern C.6<\/sup> 1<\/sup>Clinique Universitaire St. Luc, Belgium; 2<\/sup>Katharinenhospital, Stuttgart, Germany; 3<\/sup>Gent University Hospital, Belgium; 4<\/sup>Klinikum der Universit\u00e4t M\u00fcnchen, LMU, Germany; 5<\/sup>Hospital Universitari de Bellvitge, Spain; 6Roche Diagnostics GmbH Mannheim, Germany.<\/span>
\n
\nQMS\u00ae TEICOPLANIN IMMUNOASSAY: AN IMMUNOASSAY FOR THE QUANTITATIVE DETERMINATION OF TEICOPLANIN
\nCheung C<\/span>, Arabshahi L, Li H. Clinical Diagnostics Division, Thermo Fisher Scientific, Fremont, CA, USA.<\/span>
\n
\nULTRA HIGH THROUGHPUT ANALYSIS OF IMMUNOSUPPRESSANTS IN WHOLE BLOOD BY MICROFLOW LC-MS\/MS.<\/span>
\nBlake, D; Jarvis M.
\n
\nDETERMINARION OF ANAGRELIDE IN HUMAN PLASMA BY A VALIDATED LC-MS\/MS METHOD.<\/span>
\nSvinarov D<\/span>, Kasabova L, Kostova K. Central Laboratory of Therapeutic Drug Management and Clinical Pharmacology, Alexander University Hospital, Faculty of Medicine, Medical University, Sofia, Bulgaria.<\/span>
\n
\nA NEWLY DEVELOPED UPLC\/MS\/MS CLINICAL RESEARCH METHOD FOR THE ANALYSIS OF METHOTREXATE IN SERUM WAS COMPARED WITH TWO IMMUNOASSAYS.<\/span>
\nCooper DP1<\/sup>, Eastwood MP1<\/sup>, Monaghan PJ2<\/sup>, Thomson Y2<\/sup>, Calton LJ1<\/sup>. 1<\/sup>Waters Corporation, Atlas Park, Manchester, M22 5PP, UK. 2<\/sup>The Christie Hospital NHS Foundation Trust, Manchester, M20 4BX, UK.<\/span>
\n
\nAN OLD-FASHIONED LOVE SONG: HARMONIZATION OF ROUTINE TACROLIMUS MEASUREMENTS BY LC-MS<\/span>
\nMason D<\/span>1<\/sup>, Annesley T2<\/sup>, Champarnaud E3<\/sup>, Mussell C3<\/sup>, Harter L4<\/sup>, Calton L4<\/sup>, McKeown D5<\/sup>. 1<\/sup>Waters Corporation, 34 Maple Street, Milford, MA 01757. 2<\/sup>The University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109. 3<\/sup>Chemical Measurement and Calibration, LGC Limited, Teddington, TW11 0LY, UK. 4<\/sup>Waters Corporation, Atlas Park, Simonsway, Manchester, M22 5PP, UK. 5<\/sup>Analytical Services International Ltd, London, SW17 0RE, UK.<\/span>
\n
\nHPLC DETERMINATION OF VANCOMYCIN AND ITS CRYSTALLINE DEGRADATION PRODUCTS RELEASED FROM BONE GRAFTS<\/span>
\nKlapkova E<\/span>1<\/sup>, Prusa R1<\/sup>, Melichercik P2<\/sup>. 1<\/sup>Department of Medical Chemistry and Clinical Biochemistry, Charles University 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. 2<\/sup>Department of Orthopaedics, Charles University 1st Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.<\/span>
\n
\nMULTICENTER METHOD EVALUATION OF THE ARK\u2122 METHOTREXATE IMMUNOASSAY.<\/span>
\nGodefroid M<\/span>1<\/sup>, von Meyer A2<\/sup>, Parsch H3<\/sup>, Streichert T4<\/sup>, Verstraete AG1<\/sup>, Stove V1<\/sup>. 1<\/sup>Laboratory of Clinical Biology, Ghent University Hospital and Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium. 2<\/sup>St\u00e4dtisches Klinikum M\u00fcnchen GmbH, Department Klinische Chemie, Munich, Germany. 3<\/sup>Central Laboratory, University Hospital Erlangen, Germany. 4<\/sup>Zentrallaboratorien Universit\u00e4tsklinikum Eppendorf, Institut f\u00fcr Klinische Chemie, Hamburg, Germany.<\/span>
\n
\nQMS\u00ae EVEROLIMUS IMMUNOASSAY \u2013 TDM FOR KIDNEY, HEART AND LIVER TRANSPLANT PATIENTS RECEIVING EVEROLIMUS THERAPY.<\/span>
\nYokobata K, Cheung C, Lee C, Arabshahi L, Li, H<\/span>. Clinical Diagnostics Division, Thermo Fisher Scientific, Fremont, CA, USA.<\/span>
\n
\nSIMULTANEOUS MEASUREMENT OF IRINOTECAN AND ITS METABOLITES IN HUMAN PLASMA BY HPLC WITH FLUORESCENCE DETECTION .<\/span>
\nShibasaki-Hirano H<\/span>1<\/sup>, Minowa Y1<\/sup>, Ayukawa H1<\/sup>, Yokokawa A1<\/sup>, Hosoda K2<\/sup>, Ishii K2<\/sup>, Nagashima F3<\/sup>, Furuse J3<\/sup>, Furuta T1<\/sup>. 1<\/sup>Tokyo University of Pharmacy and Life Sciences, School of Pharmacy 2<\/sup>Kyorin University School of Health Sciences. 3<\/sup>Kyorin University School of Medicine.<\/span>
\n
\nLC-MS\/MS METHOD FOR THE QUANTIFICATION OF INFLIXIMAB IN HUMAN BLOOD.<\/span>
\nH. Nakamura<\/span>, T. Araki, T. Nakamura, K. Yamamoto. Department of Clinical Pharmacology, Gunma University Graduate School of Medicine, Maebashi, Japan. Department of Pharmacy, Gunma University Hospital, Maebashi, Japan.<\/span>
\n
\nPHARMACOGENETICS ALGORITHMS FOR INDIVIDUALIZING WARFARIN DOSING: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS.<\/span>
\nHui-Lin Tang1<\/sup>, Xiao-Guang Li1<\/sup>, Ting Zhang1<\/sup>, Hong-Guang Xie2<\/sup>, Suo-Di Zhai1<\/sup>. 1<\/sup>Department of Pharmacy, Peking University Therapeutic Drug Monitoring and Clinical Toxicology Center, Peking University Third Hospital, Beijing, China. 2<\/sup>General Clinical Research Center and Division of Clinical Pharmacology, Nanjing Medical University Nanjing First Hospital, Nanjing, China.<\/span>
\n
\nDETERMINATION OF RIBAVIRIN IN HUMAN PLASMA BY LC-MS\/MS.<\/span>
\n\u00d6stervall J<\/span>1<\/sup>, \u00d6stlund A1<\/sup>, Pohanka A2<\/sup>. 1<\/sup>Department of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden. 2<\/sup>Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.<\/span>
\n
\nA HIGHLY SELECTIVE, ROBUST AND SIMPLE ACCURATE MASS MS\/MS DRUG SCREENING METHOD USING THE TRIPLETOF\u00ae 5600+ SYSTEM.<\/span>
\nSeegmiller J.<\/span>1<\/sup>, Moshin J.1<\/sup> , Taylor A.M.2<\/sup> and Jarvis M.J.Y.2<\/sup>. 1<\/sup>AB SCIEX, 353 Hatch Drive, Foster City, CA. 2<\/sup>AB SCIEX, 71 Four Valley Drive, Concord, ON, Canada, L4K 4V8.
\n
\nAPPLICATION OF ULTRA HIGH LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY TO THE ANALYSIS OF THREE ATYPICAL ANTIPSYCHOTICS AND ONE ANTIDEPRESSANT: RISPERIDONE ,9-OH RISPERIDONE, ARIPIPRAZOLE ,DEHYDRO-ARIPIPRAZOLE, ZIPRASIDONE, VENLAFAXINE AND O-DESMETHYL-VENLAFAXINE (ODES) IN SERUM AND PLASMA.<\/span>
\nJuenke J.M.1<\/sup>, Brown P.I.1<\/sup>, and Johnson-Davis K.L.1,2<\/sup>. 1<\/sup>ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT. 2<\/sup>Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT.<\/span>
\n
\nEFFECT OF BREAST CANCER RESISTANCE PROTEIN ON CIMETIDINE TRANSPORT ACROSS THE PLACENTAL MODEL USING DIFFERENTIATING HUMAN CHORIOCARCINOMA JEG-3 CELLS.<\/span>
\nK. Ikeda, C. Ueda, Y. Yagi, H. Ogura, S. Kawanishi, Y. Hatsuda, S. Nishii and M. Ogawa. Laboratory of Practical Pharmacy and Pharmaceutical Care, Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan.<\/span>
\n
\nDETERMINATION OF WARFARIN IN HUMAN PLASMA BY UPLC AND ITS CLINICAL APPLICATION.<\/span>
\nYuangao Zou, Hong Jiang, Yi Li, Yun Liao, Jie Chen, Lanlan Wang. Department of Laboratory Medicine, West China Hospital of Sichuan University, Sichuan Province, People’s Republic of China. Co-Corresponding authors: Lanlan Wang , Prof. Email: wanglanlan999@163.com<\/a>.<\/span>
\n
\nVALIDATION OF AN LC\/UV METHOD FOR PIPERACILLIN\/TAZOBACTAM MONITORING IN CRITICALLY ILL PATIENTS.<\/span>
\nZuf\u00eda L<\/span>, Aquerreta I. Aldaz A. Pharmacy Department, Cl\u00ednica Universidad de Navarra, c\/ P\u00edo XII 36, 31008 Pamplona, Spain.<\/span>
\n
\nVALIDATION OF AN LC\/UV METHOD BASED ON ACCURACY PROFILES FOR DAILY 5-FLUOROURACIL DOSE ADJUSTMENT IN CANCER PATIENTS.<\/span>
\nZuf\u00eda L<\/span>, Eg\u00fces A, Aldaz A. Pharmacy Department, Cl\u00ednica Universidad de Navarra, c\/ P\u00edo XII 36, 31008 Pamplona, Spain.<\/span>
\n
\nMULTIELEMENT DETERMINATION OF K, Ca, Mg, Li, Cu, Zn, Rb, Fe, B, P, and Si IN BIOLOGICAL MATRICES USING SIMULTANEOUS INDUCTIVELY COUPLED PLASMA OPTICAL EMISSION (ICP-OES) DETECTION.<\/span>
\nBlum LM<\/span>, Rieders NF, Fucsk\u00f3 J. NMS Labs, Willow Grove, PA 19090.<\/span>
\n
\nEVALUATING THE URINE MATRIX EFFECTS IN LC-MS\/MS ANALYSIS FOLLOWING FILTRATION FOR PAIN MANAGEMENT COMPOUNDS.<\/span>
\nMarc J. Rumpler<\/span>, Lindsay A. L. Bazydlo, Timothy J. Garrett, Bruce A. Goldberger
\nDepartment of Pathology, College of Medicine, University of Florida, Gainesville, Florida.<\/span>
\n
\nDEVELOPMENT, DESIGN AND VALIDATION OF AN LC-MS\/MS METHOD FOR MORPHINE AND METABOLITES IN HUMAN PLASMA: FOCUS ON MATRIX EFFECTS USING STRAIGHT PHASE CHROMATOGRAPHY.<\/span>
\nAndersson M<\/span>, Bjorkhem-Bergman L and Beck O. Department of Laboratory Medicine, division of Clinical Pharmacology, Karolinska Institute and University Hospital, Stockholm, Sweden.<\/span>
\n
\nCOMPREHENSIVE TOXICOLOGICAL SCREENING USING GENERIC MS\/MSALL ACQUISITION ON A Q-TOF TANDEM MASS SPECTROMETER.<\/span>
\nJarvis M.<\/span>1<\/sup>, Seegmiller J.2<\/sup>, Moshin J.2<\/sup> and Taylor A.1<\/sup>. 1<\/sup>AB SCIEX, Concord, Canada; 2<\/sup>AB SCIEX, Foster City, USA.<\/span>
\n
\nPHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF MYCOPHENOLIC ACID IN de novo<\/em> KIDNEY TRANSPLANT PATIENTS.<\/span>
\nMinh Thuan Nguyen Thi<\/span>, Michel Mourad, Arnaud Capron, Flora Musuamba Tshinanu, Marie-Fran\u00e7oise Vincent, Pierre Wallemacq. Universit\u00e9 catholique de Louvain, Louvain center for Toxicology and Applied Pharmacology (LTAP), Brussels.<\/span>
\n
\nEVALUATION OF THE NOVEL ELECSYS CYCLOSPORINE A ASSAY COMPARED TO LC-MS\/MS, ABBOTT ARCHITECT AND SIEMENS DIMENSION.<\/span>
\nVerstraete A.<\/span>1<\/sup>, Shipkova M.2<\/sup>, Wallemacq, P.3<\/sup>, Vogeser M.4<\/sup>, Al\u00eda P.5<\/sup>,Widmann M.6<\/sup>. 1<\/sup>Gent University Hospital, Belgium; 2<\/sup>Katharinenhospital, Stuttgart, Germany; 3<\/sup>Clinique Universitaire St. Luc, Belgium; 4<\/sup>Klinikum der Universit\u00e4t M\u00fcnchen, LMU, Germany; 5<\/sup>Hospital Universitari de Bellvitge, Spain; 6<\/sup>Roche Diagnostics GmbH Mannheim, Germany.<\/span>
\n
\nARK\u2122 HOMOGENEOUS ENZYME IMMUNOASSAYS FOR VORICONAZOLE AND POSACONAZOLE.<\/span>
\nOh, S.<\/span>, Moon, B., Valdez, J. ARK Diagnostics, Inc., Fremont, CA.<\/span>
\n
\nINFLUENCE OF MESALAZINE ON THIOPURINE S-METHYLTRANSFERASE ACTIVITY.<\/span>
\nOuteda-Mac\u00edas M<\/span>, Salvador-Garrido P, Mart\u00ednez-L\u00f3pez LM, Mart\u00edn-Herranz I. Pharmacy Service. University Hospital of A Coru\u00f1a. Xerencia de Xesti\u00f3n Integrada A Coru\u00f1a. A Coru\u00f1a. Spain.<\/span>
\n
\nEVALUATION OF LEVETIRACETAM ARKTM ASSAY ON THE ABBOTT ARCHITECTTM ANALYSER.<\/span>
\nOuteda-Mac\u00edas M<\/span>, Salvador-Garrido P, Mart\u00ednez-L\u00f3pez LM, Mart\u00edn-Herranz I. Pharmacy Service. University Hospital of A Coru\u00f1a. Xerencia de Xesti\u00f3n Integrada A Coru\u00f1a. A Coru\u00f1a. Spain.<\/span>
\n
\nA TACROLIMUS METHOD COMPARISON BETWEEN QMS(R) PERFORMED IN A INDIKO ANALYZER AND LC-MS\/MS IN RENAL AND LIVER TRANSPLANT PATIENTS.<\/span>
\nM\u00e1s-Serrano P. Hospital General Universitario de Alicante. Clinical Pharmacokinetic Unit. Pharmacy Department. Hospital General Universitario de Alicante (Alicante, Spain). Authors: M\u00e1s-Serrano P<\/span>, Pastor C, Nalda-Molina R, Ram\u00f3n-L\u00f3pez A, Palacios E, Garc\u00eda R, Rodr\u00edguez-Laiz G, Lluis F, Selva J. Institutional affiliations: Pharmacy Department and Surgical Department from Hospital General Universitario de Alicante (Alicante, Spain). Divisi\u00f3n de Farmacia y Tecnolog\u00eda Farmac\u00e9utica. Universidad Miguel Hern\u00e1ndez (Elche, Spain)
\n
\nSIMPLE HPLC-UV METHOD FOR MYCOPHENOLIC ACID (MPA) MONITORING IN PLASMA<\/span>
\nKunicki P.K.<\/span>, Boczek A., Wa\u015b J. Clinical Pharmacology Unit, Institute of Cardiology, Warsaw, Poland.<\/span>
\n
\nUPLC-MS\/MS METHOD APPLIED FOR THE ANALYSIS OF 4 PRIMARY IMMUNOSUPPRESSIVE AGENTS IN PATIENTS\u2019 SAMPLES<\/span>
\nKunicki P.K.<\/span>, Boczek A., Wa\u015b J. Clinical Pharmacology Unit, Institute of Cardiology, Warsaw, Poland.<\/span>
\n
\nPRACTICAL APPROACH OF NEW LC-MS\/MS METHOD FOR MONITORING TACROLIMUS IN WHOLE BLOOD OF PATIENTS AFTER KIDNEY TRANSPLANTATION.<\/span>
\nBodnar-Broniarczyk M1<\/sup>, Czaplicka K1<\/sup>, Pawinski T<\/span>1<\/sup>, Majchrzak J2<\/sup>, Durlik M2<\/sup>. 1<\/sup>Department of Drug Chemistry, Medical University of Warsaw, Warsaw, Poland. 2<\/sup>Department of Transplantation Medicine and Nephrology, Medical University of Warsaw, Warsaw, Poland.<\/span>
\n
\nPERFORMANCE OF A NEW IMMUNOASSAY TO MEASURE TACROLIMUS.<\/span>
\nHolt D<\/span>1<\/sup>, Moreton-Clack M1<\/sup>, Hayward V1<\/sup>, Dickson L1<\/sup>, Johnston A1<\/sup> and Wallemacq P2<\/sup>. 1<\/sup>Analytical Services International, St George\u2019s University of London, London, UK. 2<\/sup>Laboratory of Analytical Biochemistry, University Hospital St Luc, Brussels, BELGIUM.
\n
\nMERCURY AMNESIA: A SIMPLE AND ROBUST MERCURY WHOLE BLOOD ASSAY USING INDUCTIVELY COUPLED PLASMA – MASS SPECTROMETRY (ICP-MS) WITHOUT MEMORY EFFECTS<\/span>
\nParker R.<\/span>1<\/sup>, Haglock C.J.2<\/sup>, Strathmann F.G.2,3<\/sup>. 1<\/sup>ARUP Laboratories, Salt Lake City, UT; 2<\/sup>ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT; 3<\/sup>University of Utah, Department of Pathology, Salt Lake City, UT.<\/span>
\n
\nASSAY OF THE THIOPURINE NUCLEOTIDES FOR TDM USING HPLC-MS\/MS COMPARED TO HPLC-UV IN WHOLE BLOOD.<\/span>
\nNorris R<\/span>1,2,3<\/sup>, Duley J1,3<\/sup>, Esmail L1,3<\/sup>, George R1<\/sup>, Florin T1,4<\/sup>. 1<\/sup>Mater Pathology & Mater Medical Research Institute, South Brisbane, Australia. 2<\/sup>School of Pharmacy Griffith University, Gold Coast, Australia. 3<\/sup>School of Pharmacy, University of Queensland, PACE, Woolloongabba, Australia. 4<\/sup>Department of Medicine, The University of Queensland, St Lucia, QLD.<\/span>
\n
\nSIMULTANEOUS DETERMINATION OF CISPLATIN, HYDROXO COMPLEXES, AND OH-DIMER USING HPLC.<\/span>
\nRyuji Kato<\/span>1<\/sup>, Takaji Sato2<\/sup>, Shoichi Yoshikai1<\/sup>, Kyohei Ogawa1<\/sup>, Takahiro Ogawa1<\/sup>, Daiki Kobata1<\/sup>, Kazuhiko Tanaka3<\/sup>, Yoshio Ijiri1<\/sup>, Tetsuya Hayashi1<\/sup>. 1<\/sup>Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences. 2<\/sup>Laboratory of Analytical Chemistry, Osaka University of Pharmaceutical Sciences. 3<\/sup> Kidney Center, Shirasagi Hospital.
\n
\nEVALUATION OF THE CHROMSYSTEMS\u00ae IMMUNOSUPPRESSANTS KIT ON AN ALLIANCE\/QUATTRO PREMIER XE SYSTEM AND COMPARISON OF CYCLOSPORINE A (CSA), TACROLIMUS (TAC) AND EVEROLIMUS (EVR) BLOOD CONCENTRATIONS WITH WATERS\u00ae MASSTRACK KIT AND IMMUNOASSAY IN TRANSPLANTED PATIENTS.<\/span>
\nFlornoy A, Villard C, Lacarelle B, Sampol-Manos E<\/span>. Pharmacokinetic and Toxicology Department, Timone Hospital, Marseille, France.<\/span>
\n
\nANALYSIS OF SERUM FROM TRAUMATIC BRAIN INJURY PATIENTS BY A HIGH RESOLUTION MASS SPECTROMETRY COMPREHENSIVE DRUG SCREEN.<\/span>
\nShugarts S.B.<\/span>, Thoren K, Lynch K.L., Wu AHB. Department of Laboratory Medicine, University of California, San Francisco and San Francisco General Hospital, CA 94110.<\/span>
\n
\nA NEW DETERMINATION METHOD OF EPOXYEICOSATRIENOIC AND DIHYDROXYEICOSATRIENOIC ACIDS BY LC-MS\/MS.<\/span>
\nToda T<\/span>1<\/sup>, Mukai Y1<\/sup>, Takeuchi S1<\/sup>, Senda A1<\/sup>, Hayakawa T1<\/sup>, Inotsume N1<\/sup>, Rane A2<\/sup>, Eliasson E2<\/sup>. 1<\/sup>Hokkaido Pharmaceutical University School of Pharmacy; 2<\/sup>Karolinska Instututet.<\/span>
\n
\nEFFECT OF HEMOLYSIS, ICTERUS, AND LIPEMIA ON THREE ACETAMINOPHEN ASSAYS.<\/span>
\nZhang, Y.<\/span>, Kwong, T., Kellogg, M. University of Rochester Medical Center, Rochester, NY 14618, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA 02115.<\/span>
\n
\nQMS TEICOPLANIN SERUM IMMUNOASSAY PERFORMANCE ON THE THERMO SCIENTIFIC INDIKO PLUSAND COMPARISON TO FLUORESCENCE POLARIZATION IMMUNOASSAY.<\/span>
\nDe Sloovere M.M.W.<\/span>, Verstraete A.G., Hollebosch M., Van Caeneghem E., Stove V.. Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium.<\/span>
\n
\nADAPTATION OF URINE CEDIA BENZODIAZEPINE AND BARBITURATE ASSAYS FOR THE ANALYSIS IN SERUM AND EVALUATION OF DRI TRICYCLIC SERUM TOX ASSAY ON THE THERMO SCIENTIFIC INDIKO PLUS<\/span>
\nDe Sloovere M.M.W.<\/span>, Stove V., Hollebosch M., Van Caeneghem E., Verstraete A.G. Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

1500-1600 MONDAY AFTERNOON AN INTERNATIONAL INTERLABORATORY QUALITY CONTROL (QC) PROGRAM FOR BIO-ANALYSIS OF TUBERCULOSIS DRUGS. Aarnoutse R1,2, Robijns K2, Harteveld A2, Greijdanus B3, Uges D2,3, Touw D2, Alffenaar J.W.3 1 Dept. of Pharmacy, Radboud University Medical Centre, Nijmegen, The Netherlands, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"open","template":"","meta":[],"_links":{"self":[{"href":"http:\/\/iatdmct.com\/index.php?rest_route=\/wp\/v2\/pages\/506"}],"collection":[{"href":"http:\/\/iatdmct.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/iatdmct.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/iatdmct.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/iatdmct.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=506"}],"version-history":[{"count":137,"href":"http:\/\/iatdmct.com\/index.php?rest_route=\/wp\/v2\/pages\/506\/revisions"}],"predecessor-version":[{"id":1577,"href":"http:\/\/iatdmct.com\/index.php?rest_route=\/wp\/v2\/pages\/506\/revisions\/1577"}],"wp:attachment":[{"href":"http:\/\/iatdmct.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=506"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}